Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ocumension Therapeutics ( (HK:1477) ) has provided an update.
Ocumension Therapeutics announced the resignation of Dr. Wei Li from his role as a non-executive director, who is stepping down to focus on other engagements. Subsequently, Dr. Qin Xie has been appointed as a new non-executive director, effective January 16, 2025. Dr. Xie brings extensive experience in the pharmaceutical industry, having served in various strategic roles across multiple companies, enhancing the company’s strategic development. Her appointment reflects the company’s ongoing efforts to strengthen its leadership team and strategic development.
More about Ocumension Therapeutics
Ocumension Therapeutics is a company incorporated in the Cayman Islands, primarily involved in the pharmaceuticals-related industry. It operates along with its subsidiaries and is listed on the Hong Kong Stock Exchange.
YTD Price Performance: -17.33%
Average Trading Volume: 1,438,654
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$3.07B
See more insights into 1477 stock on TipRanks’ Stock Analysis page.